ClinicalTrials.gg

Program

KYLO-0603

A development code. Also written as “Kylo 0603 Capsule 8mg”, “Kylo 0603 Capsule 12mg” and “Kylo 0603 Capsule 16mg”.

In Sino Biopharmaceutical's pipeline, THR-β激动剂. Its studies are mostly in Non-alcoholic Fatty Liver Disease, led by 2 companies.

Furthest: phase 2, since Apr 10, 20242 company-led studies, 1 open or runningNext primary completion: Aug 15, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kylonova (Xiamen) Biopharma10 open or runningphase 1since Apr 10, 2024Apr 10, 2024none ahead
Sino Biopharmaceutical11 open or runningphase 2since Sep 24, 2026Sep 24, 2026Aug 15, 2027phase 2 · NCT07878091
  • Named in Sino Biopharmaceutical’s own pipeline as Kylo-0603, phase 1, as of Nov 16, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 10, 2024First study: phase 1 study in Non-alcoholic Fatty Liver DiseaseNew to Kylonova (Xiamen) BiopharmaKylonova (Xiamen) Biopharma · NCT06365580 · 132 enrolled · China
  2. Sep 24, 2026Sino Biopharmaceutical's first study: phase 2 study in Metabolic Dysfunction-Associated Steatoic Liver DiseaseNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT07878091 · 120 planned · China

Ahead

  1. Aug 15, 2027Primary completion: phase 2 study in Metabolic Dysfunction-Associated Steatoic Liver DiseaseSino Biopharmaceutical · NCT07878091

TargetBeta

“THR-β激动剂”the company's pipeline, read by Claude · source

Other programs on THRB

ProgramCompanyFurthest phaseStudies
resmetiromruleMadrigal Pharmaceuticalsphase 422
CG-0416rulehongkong-curegene-innovation-co-limitedphase 11
KPC000154rulekunming-pharmaceuticals-incphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07878091Metabolic Dysfunction-Associated Steatoic Liver Disease · China2Not yet recruitingSino BiopharmaceuticalAug 15, 2027120
NCT06365580Non-alcoholic Fatty Liver Disease · China1CompletedKylonova (Xiamen) BiopharmaAug 16, 2024132

How it is read

Names in the registry

  • “Kylo 0603 Capsule 8mg”, 1 entry
  • “Kylo 0603 Capsule 12mg”, 1 entry
  • “Kylo 0603 Capsule 16mg”, 1 entry
  • “Kylo-0603 capsule”, 1 entry

Codes read as this program: KYLO0603.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.